Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocri

Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB) is a phase 2, interventional study registered as NCT07016230 by Gustave Roussy, Cancer Campus, Grand Paris, with a registry enrolment figure of 40 participants, started 2025-07-02 and due to reach its primary completion in 2027-05-18. Interventions recorded: Tarlatamab. Conditions listed: Metastatic/Locally Advanced Small-Cell Lung Cancer; Metastatic/Locally Advanced Poorly Differentiated NEC. Primary outcome: To estimate the objective response rate (ORR). Lung eligibility wording from the registry: "Patients with histologically confirmed diagnosis of metastatic/locally advanced SCLC with any level of DLL3 expression (Cohort 1) or other poorly differentiated NECs whatever the primary based on the most recent biopsy of a metastatic site". Sites: France. No results are recorded here; the registry entry is the source.